Skip to Content

D.H.E. 45 (dihydroergotamine) Disease Interactions

There is 1 disease interaction with D.H.E. 45 (dihydroergotamine):

Major

Ergot alkaloids (Includes D.H.E. 45) ↔ vasospastic reactions

Severe Potential Hazard, High plausibility. Applies to: Liver Disease, Shock, Peripheral Arterial Disease, Sepsis, Renal Dysfunction, Ischemic Heart Disease, Hypertension

The use of ergot alkaloids is contraindicated in patients with conditions predisposing them to vasospastic reactions, including, ischemic heart disease (angina, history of myocardial infarction, silent ischemia), peripheral vascular disease, sepsis, shock, vascular surgery, uncontrolled hypertension, and severely impaired hepatic or renal function. The vasoconstriction produced be ergot alkaloids may exacerbate these conditions. Ergot alkaloids may cause vasospastic reactions other than coronary artery vasospasm such as peripheral vascular reactions, and colonic ischemia, causing muscle pains, numbness, coldness, pallor, and cyanosis of the digits. In patients with compromised circulation, persistent vasospasm may result in gangrene or death. Nitroprusside and heparin have been used to treat ergotamine- induced severe vasoconstriction.

References

  1. "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.

D.H.E. 45 (dihydroergotamine) drug interactions

There are 645 drug interactions with D.H.E. 45 (dihydroergotamine)

D.H.E. 45 (dihydroergotamine) alcohol/food interactions

There are 3 alcohol/food interactions with D.H.E. 45 (dihydroergotamine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide